<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04577742</url>
  </required_header>
  <id_info>
    <org_study_id>2020/106</org_study_id>
    <nct_id>NCT04577742</nct_id>
  </id_info>
  <brief_title>Uveal Melanoma and Brachytheraphy: Long-term Outcomes.</brief_title>
  <official_title>Long-term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federico II University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Federico II University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigated the visual and anatomical outcomes, tumor control, tumor recurrence,&#xD;
      distant metastasis and cancer free survival in patients affected by uveal melanoma and&#xD;
      undergoing Ru-106 plaque brachytherapy between February 2011 and March 2020&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2011</start_date>
  <completion_date type="Actual">March 30, 2020</completion_date>
  <primary_completion_date type="Actual">March 20, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate long-term outcomes in patients underwent brachytherapy for uveal melanoma</measure>
    <time_frame>Mean follow-up was 4 years (3 months-9 years)</time_frame>
    <description>To investigate the visual and anatomical outcomes, tumor control, tumor recurrence, distant metastasis and cancer free survival</description>
  </primary_outcome>
  <enrollment type="Actual">350</enrollment>
  <condition>106 Ruthenium Plaque Brachytherapy</condition>
  <condition>Uveal Melanoma</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>106 Ruthenium plaque brachytherapy</intervention_name>
    <description>All patients, affected by uveal melanoma, were treated with 106 Ruthenium plaque brachytherapy to a total dose of 100 Gy to the tumor apex. The time of implant duration was calculated according to the conventional central-axis-point dose calculation</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The participans were older than 40 years with uveal melanoma and they underwent Ruthenium&#xD;
        106 brachytherapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age older than 40 years&#xD;
&#xD;
          -  diagnosis of uveal melanoma&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age older than 80 years&#xD;
&#xD;
          -  No diagnosis of uveal melanoma&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>University of Naples &quot;Federico II&quot;</name>
      <address>
        <city>Naples</city>
        <zip>80100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 3, 2020</study_first_submitted>
  <study_first_submitted_qc>October 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 3, 2020</last_update_submitted>
  <last_update_submitted_qc>October 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Federico II University</investigator_affiliation>
    <investigator_full_name>Gilda Cennamo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Uveal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

